Possible involvement of the chromosome region 10q24→q26 in early stages of melanocytic neoplasia

doi:10.1016/0165-4608(88)90200-2

Cancer Genetics and Cytogenetics

Volume 30, Issue 2, February 1988, Pages 313-317

https://doi.org/10.1016/0165-4608(88)90200-2 Get rights and content

Abstract

A recent report described a translocation involving 10q24 in a compound nevus. We have examined our series of melanocytic tumors ranging from common nevi to metastatic melanomas with the following results. In 24 nevi (congenital or common acquired), no karyotypically abnormal clones were found. Two of 10 dysplastic nevi had abnormal clones: one had an unidentified marker chromosome, the other had a t(9;10)(p24;q24) translocation. Of the three complex primary melanomas studied (lesions with both radial and vertical growth phase present), one had a t(10;?)(q26;?) and one showed a loss of chromosome 10. Among 51 advanced melanomas (primary and metastatic), all but one had multiple alterations, and 18 of these had lost one or more copies of chromosome 10. The one invasive melanoma without multiple abnormalities had a complex three-way rearrangement: 46,XY,t(5;6;10) with breakpoints on chromosome 10 at both q23 and q25. These data support the view that the terminal region of 10q may harbor one or more genes involved in the early stages of melanocytic neoplasia.

References (14)

JM Trent et al.
Chromosome 6q involvement in human malignant melanoma
Cancer Genet Cytogenet
(1983)
G Balaban et al.
Cytogenetics of human malignant melanoma and premalignant lesions
Cancer Genet Cytogenet
(1984)
G Balaban et al.
Karyotypic evolution in human malignant melanoma
Cancer Genet Cytogenet
(1986)
A Richmond et al.
Growth factor and cytogenetic abnormalities in cultured nevi and malignant melanomas
J Invest Dermatol
(1986)
ID Dubé et al.
A new translocation, t(10;14)(q24;q11), in T cell neoplasia
Blood
(1986)
R Becher et al.
Non-random chromosome changes in malignant melanoma
Cancer Res
(1983)
S Pathak et al.
Involvement of chromosome 6 in rearrangements in human malignant melanoma cell lines
Cytogenet Cell Genet
(1983)

There are more references available in the full text version of this article.

Cited by (91)

Melanoma
2022, Genomic and Precision Medicine: Oncology, Third Edition
Melanoma
2013, Genomic and Personalized Medicine
Melanoma
2012, Genomic and Personalized Medicine
Genetic progression of metastatic melanoma
2004, Cancer Letters
Melanoma progression is well defined in its clinical, histopathological and biological aspects, but the molecular mechanism involved and the genetic markers associated to metastatic dissemination are only beginning to be defined. The recent development of high-throughput technologies aimed at global molecular profiling of cancer is switching on the spotlight at previously unknown candidate genes involved in melanoma, such as WNT5A and BRAF. In fact, several tumor suppressors and oncogenes have been shown to be involved in melanoma pathogenesis, including CDKN2A, PTEN, TP53, RAS and MYC, though they have not been related to melanoma subtypes or validated as prognostic markers. Here, we have reviewed the published data relative to the major genes involved in melanoma pathogenesis, which may represent important markers for the identification of genetic profiles of melanoma subtypes.
Loss of heterozygosity analysis of cutaneous melanoma and benign melanocytic nevi: Laser capture microdissection demonstrates clonal genetic changes in acquired nevocellular nevi
2002, Human Pathology
The molecular pathology of the common nevocellular nevus (NCN) and its relationship to the genetic model of malignant melanoma (MM) progression has not been fully characterized. We used laser capture microdissection of archival formalin-fixed material to study 34 melanocytic lesions (19 MM and 15 NCN). Twelve of the 15 NCN were acquired, 3 of which were congenital; none had dysplastic features. Ten polymorphic markers on five chromosomal regions (1p36, 6q22-23.3, 8p22-24, 10q23, and 11q23) were selected for loss of heterozygosity (LOH) analysis, based on previous studies demonstrating involvement in MM pathogenesis and progression. Loss of heterozygosity at any allelic locus was observed in 18 of 19 (95%) MM and in 9 of 15 (60%) NCN. Of the three congenital nevi analyzed, none showed LOH at any informative locus. The frequency of allelic loss was highest in the MM at 6q22-23.3 (64%), followed by 10q23 (62%), 8p22-24 (43%), 11q23 (43%), and 1p36 (13%). In the 15 NCN, the most frequent allelic losses were detected at 6q22-23.3 (29%), 1p36 (27%), and 10q23 (25%), with lower frequencies of LOH at 11q23 (10%) and 8p22-24 (7%). LOH at a single polymorphic marker, D6S1038, was detected in 70% of the MM and in 36% of the NCN, suggesting the presence of putative tumor-suppressor genes (TSGs) critical in melanocytic neoplasia at 6q22-23.3. The presence of clonal genetic alterations in acquired NCN justifies their classification as a benign neoplasm. The pattern of LOH in NCN is not random; rather, the relative frequencies of LOH at the chromosomal regions examined are consistent with a multistep model of MM progression that begins with NCN. Molecular analysis of NCN reiterates established epidemiologic and morphologic notions that NCN are precursor lesions for MM. HUM PATHOL 33:191-197. Copyright 2002, Elsevier Science (USA). All rights reserved.
PTEN: Life as a tumor suppressor
2001, Experimental Cell Research
PTEN, a tumor suppressor located at chromosome 10q23, is mutated in a variety of sporadic cancers and in two autosomal dominant hamartoma syndromes. PTEN is a phosphatase which dephosphorylates phosphatidylinositol (3,4,5)-triphosphate (PtdIns-3,4,5-P3), an important intracellular second messanger, lowering its level within the cell. By dephosphorylating PtdIns-3,4,5-P3, PTEN acts in opposition to phosphatidylinositol 3-kinase (PI3K), which has a pivotal role in the creation of PtdIns-3,4,5-P3. PtdIns-3,4,5-P3 is necessary for the activation of Akt, a serine/threonine kinase involved in cell growth and survival. By blocking the activation of Akt, PTEN regulates cellular processes such as cell cycling, translation, and apoptosis. In this review, we will discuss the identification of PTEN, its mutational status in cancer, its role as a regulator of PI3K, and its domain structure.

View all citing articles on Scopus

View full text

Possible involvement of the chromosome region 10q24→q26 in early stages of melanocytic neoplasia

Abstract

Cancer Genet Cytogenet

Cancer Genet Cytogenet

Cancer Genet Cytogenet

J Invest Dermatol

Blood

Non-random chromosome changes in malignant melanoma

Cancer Res

Involvement of chromosome 6 in rearrangements in human malignant melanoma cell lines

Cytogenet Cell Genet